🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Catherine J. Mummery

UK Dementia Research Institute

ORCID: 0000-0002-6739-0803

Also affiliated with University College London

MedicineNeuroscience

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 13 papers. Top paper: “Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial”.

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial

The Lancet Neurology(2025)10.1016/s1474-4422(25)00024-9
N/A
1.2DataRank · unranked
41 citations

Yan Li, Eric McDade, Jorge J. Llibre‐Guerra, David B. Clifford, Alireza Atri +62 more

Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease

JAMA Neurology(2024)10.1001/jamaneurol.2024.0991
N/A
1.0DataRank · unranked
29 citations

Haiyan Liu, Guoqiao Wang, Xinyu Shi, Tobias Bittner, Marzia A. Scelsi +94 more

Regional age-related atrophy after screening for preclinical alzheimer disease

Neurobiology of Aging(2021)10.1016/j.neurobiolaging.2021.09.010
N/A
0.703DataRank · unranked
24 citations

Pamela LaMontagne, Matthew F. Glasser, Randall J. Bateman, David M. Holtzman, Igor Yakushev +10 more

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer’s disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial

medRxiv(2024)10.1101/2024.10.29.24316289
N/A
0.351DataRank · unranked
6 citations

Yan Li, Eric McDade, Jorge J. Llibre‐Guerra, David B. Clifford, Alireza Atri +63 more

Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease

Alzheimer s & Dementia(2024)10.1002/alz.13735
N/A
0DataRank · unranked
13 citations

Yan Li, Johannes Levin, Tammie L.S. Benzinger, Brian A. Gordon, Jason Hassenstab +20 more

Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials

The Journal of Prevention of Alzheimer s Disease(2024)10.14283/jpad.2024.61
N/A
0DataRank · unranked
4 citations

Jonathan Li, Ellen Ziegemeier, Sarah F. Adams, Eric McDade, David B. Clifford +34 more

Treatment‐related amyloid clearance (TRAC): a framework to characterize patients in the era of anti‐amyloid therapies

Alzheimer s & Dementia(2025)10.1002/alz.70997
N/A
0DataRank · unranked
15 citations

Jeffrey L. Cummings, Jeffrey L. Dage, Douglas Galasko, Miloš D. Ikonomović, Thomas K. Karikari +10 more

Insights into pathophysiology, biomarkers, and therapeutics in tauopathies: Proceedings of the Tau2024 Global Conference

Alzheimer s & Dementia(2025)10.1002/alz.70078
N/A
0DataRank · unranked
6 citations

James B. Rowe, Rufus Akinyemi, Jose F. Abisambra, Nicholas J. Ashton, Matthias Brendel +38 more

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

Nature Medicine(2021)10.1038/s41591-021-01369-8
N/A
0DataRank · unranked
365 citations

Martin R. Farlow, Eric McDade, David B. Clifford, Guoqiao Wang, Jorge J. Llibre‐Guerra +61 more

Remote Digital Cognitive Assessment in a Trial-Ready Alzheimer’s Cohort: A Scalable Approach for Early Intervention Studies

(2025)10.31234/osf.io/mz62t_v1
N/A
0DataRank · unranked
0 citations

Hannah Wilks, Matthew S. Welhaf, Samhita Katteri, Sarah H. Stout, Martin J. Sliwinski +19 more

Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services—part 2 of 6

Alzheimer s Research & Therapy(2021)10.1186/s13195-021-00895-4
N/A
0DataRank · unranked
108 citations

Timothy Rittman, Shabina Hayat, Carol Brayne, Frank Jessen, Kaj Blennow +38 more

Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study

The Lancet Neurology(2021)10.1016/s1474-4422(21)00139-3
N/A
0DataRank · unranked
71 citations

Rachel L. Henson, Yan Li, Anna H. Boerwinkle, Chengjie Xiong, Randall J. Bateman +29 more

Amyloid‐Related Imaging Abnormalities in the DIAN‐TU‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease

Annals of Neurology(2022)10.1002/ana.26511
N/A
0DataRank · unranked
44 citations

Jorge J. Llibre‐Guerra, Yan Li, Austin McCullough, Carsten Hofmann, Jakub Wojtowicz +49 more